Sign in
Taking peoplePhase 1

Naronapride at different doses in people with gastroparesis and healthy volunteers

Tests naronapride doses in people with gastroparesis and healthy volunteers.

Key facts

Who runs it
Dr. Falk Pharma GmbH
Where
Belgium, Germany, and Poland3 sites in 3 countriesChoose a country to see its sites
Registry title
A phase 1 multi-centre, randomized, single-blind, steady-state study to evaluate pharmacokinetics, pharmacodynamics, safety and tolerability after multiple-dose administration of three different doses of naronapride in patients with moderate idiopathic or diabetic gastroparesis compared to healthy subjects
Status
Recruiting
Phase
Phase 1
People taking part
60 people, planned
Started
16 Jul 2025
Expected to end
30 Nov 2026
Type of study
Interventional
Record updated
24 March 2026

Who can take part

AI summary

From the trial's eligibility criteria. Machine-read from the registry text on this page, so it can be wrong. The registry text below and the trial team decide who can take part.

The trial is looking for adults with moderate idiopathic or diabetic gastroparesis, and healthy volunteers for comparison. Gastroparesis means the stomach empties too slowly. The trial studies three doses of naronapride.

Age
18 Years and older
Sex
All sexes
Disease stage
Moderate gastroparesis, either idiopathic (no known cause) or caused by diabetes. Healthy volunteers can also join.

This trial has no sites in United States.

It has sites in 3 countries. Choose a country to see its sites.

Questions to ask the study team

  1. How often do I need to come in, and for how long each time?
  2. Are travel costs paid?
  3. Can I keep my own doctor?
  4. What happens if I want to stop?

Contact the study team: see the registry record

Print a page for my doctor

Data and sources

Registry record
Listed on the EU's official list of trials (CTIS).
Plain-language title
Naronapride at different doses in people with gastroparesis and healthy volunteersGenerated from the registry record. The registry title is the official one.
AI summary
From the trial's eligibility criteria. Read by machine on 14 November 2026.
Record updated
24 March 2026